A more recent phase I trial started in 2016 (NCT02780401) is studying the side effects and best dose of a DNA plasmid-based vaccine encoding three breast cancer antigens (insulin-like growth factor-binding protein [IGFBP]-2, HER2, and insulin-like growth factor [IGF]-1 receptor [1R]) for the prevention of cancer recurrence in patients with a history of non-metastatic, node-positive, HER2 negative breast cancer. Here, ERBB2 is linked to cancer.